keyword
MENU ▼
Read by QxMD icon Read
search

nodular lymphocyte predominant hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/29552367/a-case-of-chemotherapy-refractory-thrlbcl-like-transformation-of-nlphl-successfully-treated-with-lenalidomide
#1
Mamatha Siricilla, Lydia Irwin, Andres Ferber
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B cell lymphoma (THRLBCL), on the other hand, is a distinct entity classified under NHL and considered a variant of diffuse large B cell lymphoma (DLBCL). NLPHL can look morphologically and immunologically similar to THRLBCL and often poses a diagnostic challenge...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29537344/r-bendamustine-in-the-treatment-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#2
Roosa Enni Inkeri Prusila, Kirsi-Maria Haapasaari, Katja Marin, Marjukka Pollari, Ylermi Soini, Martine Vornanen, Marja-Liisa Karjalainen-Lindsberg, Taina Turpeenniemi-Hujanen, Outi Kuittinen
No abstract text is available yet for this article.
March 14, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29479868/adult-nodular-lymphocyte-predominant-hodgkin-lymphoma-treatment-modality-utilization-and-survival
#3
Clayton Alonso, Sunil W Dutta, Nandita Mitra, Daniel J Landsburg, Nicholas G Zaorsky, Surbhi Grover, Jennifer Peterson, Daniel M Trifiletti
Early-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is associated with a favorable prognosis. Our aim was to evaluate the patterns of care of radiotherapy utilization in this disease and to define the relationship between treatment modality and survival. The National Cancer Database was queried for patients with stages I-II NLPHL diagnosed from 2004 to 2012. Patients were compared based on primary therapy into four categories: radiotherapy, chemotherapy, both, or neither. Covariate-adjusted and propensity score-weighted (PS) Cox proportional hazards models were used, adjusting for potential factors confounding survival...
February 26, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29413265/coping-with-knife-postoperative-management-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#4
EDITORIAL
Shushan Rana, John Holland
No abstract text is available yet for this article.
March 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29401099/surgeon-concordance-in-the-assessment-of-resectability-for-stage-ia-nodular-lymphocyte-predominant-hodgkin-lymphoma
#5
Jennifer H Aldrink, Burton Appel, Joel A Kaplan, Robert E Hutchison, Cindy L Schwartz, Kara M Kelly, Kathleen McCarten, Peter F Ehrlich
No abstract text is available yet for this article.
February 2, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29380399/immunohistochemical-assessment-of-the-diagnostic-utility-of-pd-l1-a-preliminary-analysis-of-anti-pd-l1-antibody-sp142-for-lymphoproliferative-diseases-with-tumour-and-nonmalignant-hodgkin-reed-sternberg-hrs-like-cells
#6
Ayako Sakakibara, Kei Kohno, Ahmed E Eladl, Teerada Klaisuwan, Eri Ishikawa, Yuka Suzuki, Satoko Shimada, Masato Nakaguro, Yoshie Shimoyama, Taishi Takahara, Seiichi Kato, Naoko Asano, Shigeo Nakamura, Akira Satou
AIMS: The programmed death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumour cells escape from immune control. PD-L1 immunohistochemistry is a useful predictor of immunotherapy response, but is still not widely used in the diagnostic setting. Here we describe results using PD-L1 immunohistochemistry during routine diagnostics in lymphoma. METHODS AND RESULTS: Ninety-one lymphoproliferative disease cases sharing tumour and nonmalignant Hodgkin/Reed-Sternberg (HRS)-like cells with and without Epstein-Barr virus (EBV) association were investigated by immunohistochemistry for PD-L1 (clone SP142)...
January 30, 2018: Histopathology
https://www.readbyqxmd.com/read/29351228/erratum-lydia-visser-et-al-characterization-of-the-microenvironment-of-nodular-lymphocyte-predominant-hodgkin-lymphoma-int-j-mol-sci-2016-17-2127
#7
Ahmad Sattarzadeh, Lydia Visser, Bea Rutgers, Arjan Diepstra, Anke van den Berg
The authors regret to have made a mistake in publishing this paper [1] with an incorrect author list [...].
January 19, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29296913/clinicopathologic-consensus-study-of-gray-zone-lymphoma-with-features-intermediate-between-dlbcl-and-classical-hl
#8
Monika Pilichowska, Stefania Pittaluga, Judith A Ferry, Jessica Hemminger, Hong Chang, Jennifer A Kanakry, Laurie H Sehn, Tatyana Feldman, Jeremy S Abramson, Athena Kritharis, Francisco J Hernandez-Ilizaliturri, Izidore S Lossos, Oliver W Press, Timothy S Fenske, Jonathan W Friedberg, Julie M Vose, Kristie A Blum, Deepa Jagadeesh, Bruce Woda, Gaurav K Gupta, Randy D Gascoyne, Elaine S Jaffe, Andrew M Evens
Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). However, there remains complexity in establishing diagnosis, delineating prognosis, and determining optimum therapy. Sixty-eight cases diagnosed as GZL across 15 North American academic centers were evaluated by central pathology review to achieve consensus. Of these, only 26 (38%) were confirmed as GZL. Morphology was critical to GZL consensus diagnosis (eg, tumor cell richness); immunohistochemistry showed universal B-cell derivation, frequent CD30 expression, and rare Epstein-Barr virus (EBV) positivity (CD20+ , 83%; PAX5+ , 100%; BCL6+ , 20%; MUM1+ , 100%; CD30+ , 92%; EBV+ , 4%)...
December 12, 2017: Blood Advances
https://www.readbyqxmd.com/read/29230339/nodular-lymphocyte-predominant-hodgkin-lymphoma-of-the-ileum
#9
Aruna Rangan, Sarah W Grahn, Andrew L Feldman
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma derived from germinal center B lymphocytes that typically presents with localized lymph node involvement and can mimic a variety of both reactive and other neoplastic conditions. Extranodal involvement is uncommon in NLPHL and typically occurs in the context of previously documented or synchronous nodal disease. Involvement of the gastrointestinal tract is exceedingly rare. Here, we present the first case to our knowledge of NLPHL involving the ileum that was discovered incidentally on routine screening colonoscopy in an asymptomatic patient...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/29222274/nodular-lymphocyte-predominant-hodgkin-lymphoma-a-unique-disease-deserving-unique-management
#10
REVIEW
Dennis A Eichenauer, Andreas Engert
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA)...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29122656/programmed-death-1-ligands-pd-l1-and-pd-l2-show-distinctive-and-restricted-patterns-of-expression-in-lymphoma-subtypes
#11
Poonam K Panjwani, Vivek Charu, Monique DeLisser, Hernan Molina-Kirsch, Yasodha Natkunam, Shuchun Zhao
The success of immunotherapy using immune checkpoint blockade in solid tumors and in relapsed/refractory classical Hodgkin lymphoma and chronic lymphocytic leukemia holds promise for targeted therapy in hematologic malignancies. Because efficacy of immunomodulatory therapy is correlated with numbers of cells that express programmed death (PD-1) ligands, we evaluated the expression of PD-L1 and PD-L2 proteins using immunohistochemistry in more than 702 diagnostic lymphoma biopsies. In classical Hodgkin lymphoma, PD-L1 and PD-L2 were expressed in 82% and 41% of cases, respectively, and PD-L1 but not PD-L2 expression correlated with Epstein-Barr virus in tumor cells...
January 2018: Human Pathology
https://www.readbyqxmd.com/read/29099538/how-immunologic-and-genetic-biomarkers-impact-hodgkin-lymphoma-classification-diagnosis-and-management-a-huge-potential-that-yet-needs-to-be-exploited
#12
Antonino Carbone, Annunziata Gloghini
"Ne è passata di acqua sotto i ponti." It has been a long time since the diagnosis of Hodgkin lymphoma (HL) was exclusively based on the detection of typical Reed-Sternberg cells and the recognition of the characteristic morpho-histological background, as well as on the pathologist's skill. The discovery of immunologic, molecular genetic and virologic biomarkers has provided an objective contribution to the diagnosis and a scientific basis for a modern classification of HL. Recent updates have clarified the nature of the so-called nodular lymphocyte predominant HL and its link to the T-cell/histiocyte-rich large B-cell lymphomas as well as its relationship with the lymphocyte-rich subset of classical HL (CHL)...
October 28, 2017: International Journal of Biological Markers
https://www.readbyqxmd.com/read/29051078/the-role-of-radiation-in-all-stages-of-nodular-lymphocytic-predominant-hodgkin-lymphoma
#13
Bismarck Odei, Dustin Boothe, Jonathan Frandsen, Matthew M Poppe, David K Gaffney
BACKGROUND: The goal of this study was to assess the survival differences seen in early-stage and advanced-stage nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) based on treatment modality. PATIENTS AND METHODS: The National Cancer Database was queried to identify patients diagnosed with NLPHL between 2004 and 2012. Overall survival (OS) was determined using univariate and multivariate Cox regression analysis. Kaplan-Meier and log-rank analysis were used to estimate differences in OS between treatment groups...
December 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29034220/head-and-neck-lymphoma-in-an-iranian-population
#14
Nafiseh Shamloo, Alireza Ghannadan, Mahsa Jafari, Samane Ahmadi, Hamed Mortazavi, Maryam Baharvand
INTRODUCTION: This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population. MATERIALS AND METHODS: In this retrospective study, 126,450 biopsy reports from two referral Pathology Departments, (Tehran, the capital of Iran) were evaluated. In cases with head and neck lymphoma, other variables such as age, sex, specific location of lesions, and histopathological findings were recorded. Descriptive statistics were used to measure the prevalence and characteristics of head and neck lymphoma by means of SPSS soft ware, version 18...
September 2017: Iranian Journal of Otorhinolaryngology
https://www.readbyqxmd.com/read/28971503/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-retrospective-study-by-the-european-society-for-blood-and-marrow-transplantation-lymphoma-working-party
#15
Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, Tamas Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger
Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy...
January 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/28935378/nodular-lymphocyte-predominant-hodgkin-lymphoma-a-real-world-case-series-of-consecutive-patients-treated-by-a-single-multidisciplinary-team-in-the-east-of-england-from-1999-to-2015
#16
Jessica C Griffin, Shalal Sadullah, Lazlo Igali, Nimish K Shah, Jennifer Z Wimperis, Kristian M Bowles
No abstract text is available yet for this article.
December 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28904936/evaluation-of-urokinase-plasminogen-activator-receptor-soluble-urokinase-plasminogen-activator-receptor-and-%C3%AE-1-integrin-in-patients-with-hodgkin-s-lymphoma
#17
Shirin Kouhpayeh, Alireza Andalib, Marjan Gharagozloo, Mohammad Hossein Sanei, Nafiseh Esmaeil, Mohammad Reza Maracy
BACKGROUND: The objective of this study is to indicate the role of urokinase plasminogen activator receptor (uPAR), soluble uPAR (suPAR), and β1 integrin in tumor growth and invasion of lymph nodes from Hodgkin's lymphoma (HL) patients. MATERIALS AND METHODS: In this study, 25 lymph nodes from HL patients were analyzed for the expression of β1 integrin and uPAR on mononuclear cells using two-color flow cytometry and immunohistochemical analysis. Moreover, the levels of suPAR in the serum samples of HL patients were measured and compared with 32 healthy controls...
2017: Advanced Biomedical Research
https://www.readbyqxmd.com/read/28902084/children-and-adolescent-hodgkin-lymphoma-in-argentina-long-term-results-after-combined-abvd-and-restricted-radiotherapy
#18
Pedro A Zubizarreta, Elizabeth Alfaro, Myriam Guitter, Cristian Sanchez La Rosa, María L Galluzzo, Natalia Millán, Fernando Fiandrino, María S Felice
OBJECTIVE: Prospective analysis of clinical characteristics and long-term treatment results of a pediatric cohort with Hodgkin lymphoma (HL) treated in a single institution with ABVD and restricted radiotherapy (RT). PATIENTS AND METHODS: Between September 2000 and December 2015, 165 new consecutive assessable patients with HL were registered at our institution. Lymphocyte predominant nodular HL was excluded. Low risk (LR) patients were stage I and IIA (no bulky disease, <4 involved ganglionar areas and no lung hilar nodes), high risk (HR) was assigned to stage IV and any other stage with bulky mediastinum...
November 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28902083/nodular-lymphocyte-predominant-hodgkin-lymphoma-in-a-15-year-old-boy-with-li-fraumeni-syndrome-having-a-germline-tp53-d49h-mutation
#19
Fumito Yamazaki, Haruko Shima, Tomoo Osumi, Satoshi Narumi, Tatsuo Kuroda, Hiroyuki Shimada
Germline mutations in TP53 are the primary cause of Li-Fraumeni syndrome (LFS). Most mutations are reported within the DNA-binding domain. We report a case of a 15-year-old boy with LFS who developed early-stage nodular lymphocyte-predominant Hodgkin lymphoma, a rare subtype of Hodgkin lymphomas. His sister was diagnosed with embryonal rhabdomyosarcoma at the age of 1.5 years. Sequence analysis revealed a germline mutation in the transactivation domain of TP53, c.145G>C (p.D49H), in the patient, his sister, and father...
September 8, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28877074/gata3-immunohistochemical-staining-in-hodgkin-lymphoma-diagnostic-utility-in-differentiating-classic-hodgkin-lymphoma-from-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-other-mimicking-entities
#20
Brie Kezlarian, Mohammad Alhyari, Girish Venkataraman, Kristin Karner, Kedar V Inamdar, Madhu P Menon
BACKGROUND: Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are clinically distinct entities, with different prognostic and treatment implications. In addition, several large B-cell lymphomas and some T-cell lymphomas can mimic CHL. Differentiating these entities from CHL is crucial for ensuring appropriate therapy. GATA3 is a T-cell transcription factor involved in T-cell maturation and has been previously shown to be overexpressed in CHL cells via gene expression profiling...
September 4, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
keyword
keyword
49023
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"